Identification and Characterization of a Stem Cell-Like Population in Ovarian Cancer

dc.contributor.advisorGabrielson, Edwarden_US
dc.contributor.committeeMemberArmstrong, Deborah K.en_US
dc.contributor.committeeMemberBerman, David M.en_US
dc.contributor.committeeMemberJones, Richard J.en_US
dc.contributor.committeeMemberRoden, Richard S.en_US
dc.creatorSharrow, Allison Catherineen_US
dc.date.accessioned2014-12-23T04:39:44Z
dc.date.available2014-12-23T04:39:44Z
dc.date.created2014-05en_US
dc.date.issued2014-01-31en_US
dc.date.submittedMay 2014en_US
dc.description.abstractEighty percent of patients with advanced ovarian cancer show an initial clinical response to therapy, but seventy-five percent of these patients eventually relapse. This transient clinical response would be consistent with the cancer stem cell hypothesis. A substantial body of recent evidence supports the cancer stem cell hypothesis in ovarian cancer. However, controversy exists regarding the phenotype of ovarian cancer stem cells. Additionally, their clinical relevance remains unclear. In order to test the hypothesis that ovarian cancer contains a population of stem-like cells, aldehyde dehydrogenase 1 high (ALDHhigh) cells from two ovarian cancer cell lines with distinct subtypes were examined for cancer stem cell properties. Compared to ALDHlow cells, ALDHhigh cells displayed nonadherent growth, an absence of contact inhibition, smaller size, quiescence, the ability to regenerate the phenotypic diversity of the cell line, in vivo tumorigenicity, multi-drug resistance, and gene expression differences consistent with a stem cell phenotype. Because ALDHhigh cells phenotypically resemble cancer stem cells, studying this population in two different subtypes may reveal biological properties of ovarian cancer stem cells. Differential gene expression suggested that the ALDHhigh population had increased tight junction signaling, downregulation of tumor suppressors, increased invasion, and decreased coagulation. No consistent differences were observed in previously reported ovarian cancer stem cell markers, hormone receptors, Her-2/neu, CA125 or developmental pathways. The only ABC transporter with consistent upregulation was MDR1. The ultimate goal of studying ovarian cancer stem cells is to develop therapies to eradicate these cells. Gene expression patterns in ALDHhigh cells identified four potential therapeutic targets: mTOR, Her-2/neu, CD47 and FGF18. This project provides further support for the existence of ovarian cancer stem cells as well as the use of high aldehyde dehydrogenase 1 activity for their isolation. Few studies have comprehensively examined ovarian cancer stem cells from multiple subtypes. This work demonstrated substantial variability between the two studied subtypes. However, those features that were consistent would likely represent universal features of ovarian cancer stem cells. Finally, the potential therapeutic targets identified in this study may allow patients with ovarian cancer to achieve durable remission.en_US
dc.format.mimetypeapplication/pdfen_US
dc.identifier.urihttp://jhir.library.jhu.edu/handle/1774.2/37063
dc.languageen
dc.publisherJohns Hopkins University
dc.subjectovarian canceren_US
dc.subjectcancer stem cellsen_US
dc.subjectaldehyde dehydrogenaseen_US
dc.subjectAldefluoren_US
dc.titleIdentification and Characterization of a Stem Cell-Like Population in Ovarian Canceren_US
dc.typeThesisen_US
dc.type.materialtexten_US
thesis.degree.departmentPathobiologyen_US
thesis.degree.disciplinenot listeden_US
thesis.degree.grantorJohns Hopkins Universityen_US
thesis.degree.grantorSchool of Medicineen_US
thesis.degree.levelDoctoralen_US
thesis.degree.namePh.D.en_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
LICENSE.txt
Size:
2.68 KB
Format:
Plain Text
Description: